
Matthew Seftel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10608255/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood, 2016, 127, 2427-2438.	1.4	403
2	Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program. Blood, 2013, 121, 197-206.	1.4	123
3	Second Autologous Stem Cell Transplantation for Relapsed Lymphoma after a Prior Autologous Transplant. Biology of Blood and Marrow Transplantation, 2008, 14, 904-912.	2.0	56
4	Reduced intensity conditioned allograft yields favorable survival for older adults with B ell acute lymphoblastic leukemia. American Journal of Hematology, 2017, 92, 42-49.	4.1	46
5	Comparing Outcomes with Bone Marrow or Peripheral Blood Stem Cells as Graft Source for Matched Sibling Transplants in Severe Aplastic Anemia across Different Economic Regions. Biology of Blood and Marrow Transplantation, 2016, 22, 932-940.	2.0	43
6	Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: 10 olor flow cytometry diagnosis and HyperCVAD therapy. American Journal of Hematology, 2016, 91, 283-286.	4.1	40
7	Allotransplantation for Patients Age ≥40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival. Biology of Blood and Marrow Transplantation, 2014, 20, 960-968.	2.0	37
8	Hematopoietic Cell Transplantation as Curative Therapy forÂPatients with Myelofibrosis: Long-Term Success in all AgeÂGroups. Biology of Blood and Marrow Transplantation, 2015, 21, 1883-1887.	2.0	36
9	Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood Advances, 2022, 6, 339-357.	5.2	35
10	Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission. Biology of Blood and Marrow Transplantation, 2014, 20, 202-208.	2.0	33
11	Outcome of Lower-Intensity Allogeneic Transplantation in Non-Hodgkin Lymphoma after Autologous Transplantation Failure. Biology of Blood and Marrow Transplantation, 2012, 18, 1255-1264.	2.0	27
12	Impaired T Cell Responsiveness to Interleukin-6 in Hematological Patients with Invasive Aspergillosis. PLoS ONE, 2015, 10, e0123171.	2.5	21
13	Incidence, Risk Factors, and Long-Term Outcomes of Sclerotic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1751-1757.	2.0	15
14	A user guide to the American Society of Hematology clinical practice guidelines. Blood Advances, 2020, 4, 2095-2110.	5.2	14
15	Does Total Body Irradiation Conditioning Improve Outcomes of Myeloablative Human Leukocyte Antigen–Identical Sibling Transplantations for Chronic Lymphocytic Leukemia?. Biology of Blood and Marrow Transplantation, 2014, 20, 421-424.	2.0	13
16	Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia in Adults. Current Hematologic Malignancy Reports, 2016, 11, 175-184.	2.3	13
17	Improved prognostic stratification power of CIBMTR risk score with the addition of absolute lymphocyte and eosinophil counts at the onset of chronic GVHD. Annals of Hematology, 2017, 96, 805-815.	1.8	12
18	Burkitt's Lymphoma and B-Cell Lymphoma Unclassifiable With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt's Lymphoma in Patients With HIV: Outcomes in a South African Public Hospital. Journal of Global Oncology, 2017, 3, 218-226.	0.5	8

MATTHEW SEFTEL

#	Article	IF	CITATIONS
19	Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34+ Yields Are Less. Biology of Blood and Marrow Transplantation, 2018, 24, 175-184.	2.0	7
20	The role of hematopoietic stem cell transplantation in advanced Hodgkin Lymphoma. Transfusion and Apheresis Science, 2007, 37, 49-56.	1.0	6
21	Assessment of Impact of HLA Type on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia. Biology of Blood and Marrow Transplantation, 2018, 24, 581-586.	2.0	5
22	Bilateral adrenal hemorrhage as a manifestation of extramedullary hematopoiesis in a patient with primary myelofibrosis. Annals of Hematology, 2018, 97, 2011-2012.	1.8	3
23	Predictors of poor haematopoietic stem cell mobilisation in patients with haematological malignancies at a South African centre. Transfusion and Apheresis Science, 2022, 61, 103419.	1.0	3
24	Country-Level Macroeconomic Indicators Predict Early Post-Allogeneic Hematopoietic Cell Transplantation Survival in Acute Lymphoblastic Leukemia: A CIBMTR Analysis. Biology of Blood and Marrow Transplantation, 2018, 24, 1928-1935.	2.0	2
25	Building Canadian capacity for CARâ€T cells in relapsed/refractory acute lymphoblastic leukaemia: a retrospective cohort study. British Journal of Haematology, 2020, 191, e14-e19.	2.5	1
26	Is Haploidentical Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide Feasible in Sub-Saharan Africa?. Transplantation and Cellular Therapy, 2021, , .	1.2	1
27	Total Body Irradiation (TBI) Based Versus Chemotherapy-Based Preparative Regimens Before Autologous Stem Cell Transplant for Non-Hodgkin's Lymphoma Blood, 2007, 110, 5105-5105.	1.4	0